Der­mi­ra vets li­cense back can­di­dates from Eli Lil­ly to launch their own up­start

About a year af­ter Eli Lil­ly ab­sorbed Der­mi­ra in a $1 bil­lion buy­out, the der­ma­tol­ogy com­pa­ny’s co-founders are li­cens­ing back three in­flam­ma­to­ry dis­ease pro­grams they helped de­vel­op for their own up­start, Evom­mune.

Lil­ly had its sights set on le­brik­izum­ab, a cast-off from Roche that Der­mi­ra picked up for $135 mil­lion in near-term cash. But Der­mi­ra was al­so fo­cused on a broad­er an­ti-in­flam­ma­to­ry pipeline, ac­cord­ing to Luis Peña, Evom­mune pres­i­dent and CEO and Der­mi­ra’s co-founder and for­mer chief de­vel­op­ment of­fi­cer. That broad­er pipeline is what Evom­mune is look­ing to mine for its own ef­forts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER